Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1669-1674

  Sowa Staszczak, Anna ^a   Pach, Dorota ^a   Chrzan, Robert ^a   Trofimiuk, Małgorzata ^a   Stefańska, Agnieszka ^a   Tomaszuk, Monika ^a   Kołodziej, Maciej ^a   Mikołajczak, Renata ^b   Pawlak, Dariusz ^b   Hubalewska Dydejczyk, Alicja ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^c Department of Endocrinology ^*  (Poland)

Author keywords

Neoadjuvant therapy; Neuroendocrine tumours; Peptide receptor radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TATE Y 90; EDETATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; RADIOISOTOPE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 80455174802     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1835-8     Document Type: Article

References (12)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72. PMID 18780869.
2. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-73. PMID 15151956. (Pubitemid 39004355)
3. Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009;15:5867-70. PMID 19998512.
4. Shimizu T, Hirano A, Watanabe O, Kinoshita J, Kimura K, Kamimura M, et al. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. Anticancer Res 2010;30:581-5. PMID 20332474.
5. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclidetherapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92-9. PMID 20168291.
6. Plachcinska A, Mikolajczak R, Maecke HR, Mlodkowska E, Kunert-Radek J, Michalski A, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: A pilot study. Cancer Biother Radiopharm 2004;19:261-70. PMID 15186607. (Pubitemid 38685124)
7. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427-43.
8. Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 2010;395:185-92. PMID 19506898.
9. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16. PMID 10655437.
10. Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. PMID 19097774.
11. Choi H, Charnsangavei C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9. PMID 17470865. (Pubitemid 46797957)
12. Llovet J, Di Bisceglie A, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-710. PMID 18477802.